<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00139971</url>
  </required_header>
  <id_info>
    <org_study_id>WJTOG0101</org_study_id>
    <nct_id>NCT00139971</nct_id>
  </id_info>
  <brief_title>Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>West Japan Thoracic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West Japan Thoracic Oncology Group</source>
  <brief_summary>
    <textblock>
      To estimate the efficacy of Gemcitabine monotherapy compared to UFT as the post operative
      adjuvant chemotherapy for completely resected non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2001</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5 year survival rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
  </secondary_outcome>
  <enrollment>600</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UFT 250mg/m2, daily for 1 year</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. completely resected non small cell lung cancer

          2. no prior anti cancer treatment for thoracic malignancy exept for this operation

          3. pathological stage IB, II, and stage IIIA with only one station of n2 disease

          4. PS 0-1

          5. age 20-75

          6. adequate organ function for chemotherapy

          7. written informed consent

        Exclusion Criteria:

          1. small cell lung cancer or low grade malignancy of lung cancer

          2. incomplete resection

          3. apparent interstitial pneumonitis at chest rentogenogram

          4. inadequate condition for chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hirohito Tada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Japan Thoracic Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hirohito Tada, MD</last_name>
    <phone>+81-6-6929-1221</phone>
    <email>htada@attglobal.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Osaka City General Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>531-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hirohito Tada, MD</last_name>
      <phone>+81-6-6929-1221</phone>
      <email>htada@attglobal.net</email>
    </contact>
    <investigator>
      <last_name>Hirohito Tada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2005</study_first_posted>
  <last_update_submitted>January 5, 2006</last_update_submitted>
  <last_update_submitted_qc>January 5, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

